Sorrento Therapeutics, Inc. (SRNE) DCF Valuation
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Sorrento Therapeutics, Inc. (SRNE) Bundle
Whether you’re an investor or analyst, this (SRNE) DCF Calculator is your go-to resource for accurate valuation. Preloaded with real data from Sorrento Therapeutics, Inc., you can adjust forecasts and instantly observe the effects.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2018 |
AY2 2019 |
AY3 2020 |
AY4 2021 |
AY5 2022 |
FY1 2023 |
FY2 2024 |
FY3 2025 |
FY4 2026 |
FY5 2027 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 21.2 | 31.4 | 40.0 | 52.9 | 62.8 | 82.7 | 108.9 | 143.4 | 188.8 | 248.5 |
| Revenue Growth, % | 0 | 48.31 | 27.21 | 32.31 | 18.78 | 31.65 | 31.65 | 31.65 | 31.65 | 31.65 |
| EBITDA | -147.1 | -308.4 | -275.7 | -436.0 | -539.9 | -82.7 | -108.9 | -143.4 | -188.8 | -248.5 |
| EBITDA, % | -694.08 | -981.15 | -689.47 | -824.11 | -859.22 | -100 | -100 | -100 | -100 | -100 |
| Depreciation | 9.1 | 15.0 | 14.7 | 16.3 | 13.2 | 29.7 | 39.1 | 51.4 | 67.7 | 89.1 |
| Depreciation, % | 42.72 | 47.86 | 36.79 | 30.84 | 21.08 | 35.86 | 35.86 | 35.86 | 35.86 | 35.86 |
| EBIT | -156.2 | -323.4 | -290.4 | -452.3 | -553.2 | -82.7 | -108.9 | -143.4 | -188.8 | -248.5 |
| EBIT, % | -736.8 | -1029.01 | -726.25 | -854.95 | -880.3 | -100 | -100 | -100 | -100 | -100 |
| Total Cash | 168.6 | 22.5 | 56.5 | 126.9 | 50.0 | 74.7 | 98.3 | 129.4 | 170.3 | 224.3 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 4.4 | 14.5 | 15.5 | 18.7 | 24.5 | 29.7 | 39.1 | 51.5 | 67.8 | 89.3 |
| Account Receivables, % | 20.57 | 45.98 | 38.78 | 35.38 | 38.94 | 35.93 | 35.93 | 35.93 | 35.93 | 35.93 |
| Inventories | .0 | 3.4 | 1.8 | 8.1 | 10.0 | 7.7 | 10.1 | 13.3 | 17.5 | 23.1 |
| Inventories, % | 0 | 10.7 | 4.58 | 15.32 | 15.88 | 9.29 | 9.29 | 9.29 | 9.29 | 9.29 |
| Accounts Payable | 13.8 | 27.6 | 24.7 | 27.4 | 47.5 | 56.6 | 74.6 | 98.2 | 129.2 | 170.2 |
| Accounts Payable, % | 65.2 | 87.9 | 61.79 | 51.82 | 75.61 | 68.46 | 68.46 | 68.46 | 68.46 | 68.46 |
| Capital Expenditure | -21.2 | -11.4 | -37.6 | -8.9 | -13.7 | -44.5 | -58.6 | -77.1 | -101.5 | -133.7 |
| Capital Expenditure, % | -100.01 | -36.4 | -93.98 | -16.77 | -21.73 | -53.78 | -53.78 | -53.78 | -53.78 | -53.78 |
| Tax Rate, % | -1.98 | -1.98 | -1.98 | -1.98 | -1.98 | -1.98 | -1.98 | -1.98 | -1.98 | -1.98 |
| EBITAT | -148.7 | -323.0 | -288.5 | -419.5 | -564.1 | -80.6 | -106.1 | -139.7 | -183.9 | -242.2 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -151.4 | -319.1 | -313.8 | -418.9 | -552.0 | -89.3 | -119.6 | -157.4 | -207.2 | -272.8 |
| WACC, % | 6.08 | 6.38 | 6.35 | 5.93 | 6.39 | 6.22 | 6.22 | 6.22 | 6.22 | 6.22 |
| PV UFCF | ||||||||||
| SUM PV UFCF | -685.8 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | -278 | |||||||||
| Terminal Value | -6,588 | |||||||||
| Present Terminal Value | -4,871 | |||||||||
| Enterprise Value | -5,557 | |||||||||
| Net Debt | 111 | |||||||||
| Equity Value | -5,668 | |||||||||
| Diluted Shares Outstanding, MM | 419 | |||||||||
| Equity Value Per Share | -13.52 |
What You Will Get
- Real SRNE Financials: Access historical and projected data for precise valuation.
- Customizable Inputs: Adjust WACC, tax rates, revenue growth, and capital expenditures as needed.
- Dynamic Calculations: Intrinsic value and NPV are computed automatically.
- Scenario Analysis: Explore various scenarios to assess Sorrento’s future performance.
- User-Friendly Design: Designed for professionals while remaining approachable for newcomers.
Key Features
- Comprehensive Data: Sorrento Therapeutics’ historical financial statements and pre-filled projections.
- Customizable Variables: Adjust WACC, tax rates, revenue growth, and EBITDA margins as needed.
- Real-Time Insights: Observe Sorrento Therapeutics’ intrinsic value recalculating instantly.
- Visual Performance Metrics: Interactive dashboard charts showcase valuation results and essential metrics.
- Designed for Precision: A professional-grade tool tailored for analysts, investors, and finance professionals.
How It Works
- Download: Obtain the pre-built Excel file containing Sorrento Therapeutics, Inc. (SRNE) financial data.
- Customize: Tailor forecasts, including revenue growth, EBITDA %, and WACC to fit your analysis.
- Update Automatically: Watch as intrinsic value and NPV calculations refresh in real-time.
- Test Scenarios: Generate various projections and evaluate results immediately.
- Make Decisions: Leverage the valuation outcomes to inform your investment choices.
Why Choose Sorrento Therapeutics (SRNE)?
- Innovative Solutions: Cutting-edge therapies designed to address unmet medical needs.
- Proven Expertise: A team of seasoned professionals dedicated to advancing biotechnology.
- Robust Pipeline: A diverse range of products in various stages of development.
- Commitment to Quality: Stringent processes ensure the highest standards in research and development.
- Collaborative Approach: Partnerships with leading organizations to enhance therapeutic outcomes.
Who Should Use This Product?
- Biotechnology Students: Explore drug development processes and analyze real-world data.
- Researchers: Utilize advanced models to enhance studies in pharmaceutical innovation.
- Investors: Evaluate your investment strategies and assess valuation metrics for Sorrento Therapeutics, Inc. (SRNE).
- Market Analysts: Optimize your analysis with a tailored DCF model specific to biotech companies.
- Healthcare Entrepreneurs: Understand how major biotech firms like Sorrento Therapeutics are valued and analyzed.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Sorrento Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), featuring parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models displaying intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Sorrento Therapeutics, Inc. (SRNE).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to facilitate easy analysis of results.